EDC systems for clinical trials: the definitive guide for medical device manufacturers

Most electronic data capture (EDC) systems for clinical trials were not built with medical device manufacturers in mind. EDC software designed for pharmaceutical studies rarely maps to what device investigations actually require. The gap between a generic EDC platform and one built specifically for electronic data capture in medical device clinical trials is wide enough to affect study timelines, data quality, and regulatory submissions. GG Clinical is Greenlight Guru's purpose-built EDC for medical device clinical trials.

They were built for pharmaceutical trials: large Phase III studies with stable protocols, enterprise contract research organization (CRO) infrastructure, and IT teams whose job it is to configure and maintain the system. When device manufacturers try to use these tools for clinical investigations, they run into the same set of problems every time. The eCRFs don't flex for the variability of device studies. The workflows assume pharma-style delegation to CROs. The data ends up on the CRO's infrastructure, not the sponsor's. And setup takes months when the clinical team needed to be enrolling weeks ago.

This guide is for device manufacturers preparing for a first-in-human feasibility study, a pivotal trial under ISO 14155, or a post-market clinical follow-up (PMCF) investigation under EU Medical Device Regulation (MDR). It covers what EDC actually needs to do in a device context, why device studies are structurally different from pharmaceutical trials, what the wrong system costs you in ways that aren't always visible upfront, and what to look for when you're evaluating options.

What EDC means for device manufacturers

Electronic data capture (EDC) for medical devices is the system your clinical investigation runs on. It's where investigators enter subject data, where your clinical team monitors query status, where protocol deviations get recorded, and where your dataset lives through to database lock. In the context of medical device EDC clinical trials, the platform also carries specific responsibilities that pharma-oriented systems weren't designed to fulfill: ISO 14155 alignment, device-specific electronic case report form (eCRF) structures, and sponsor data ownership that survives the CRO relationship.

For manufacturers, this is not a CRO's tool. It's your tool. The evidence that comes out of your clinical program will support regulatory submissions, payer negotiations, and post-market obligations for the life of the device. Ceding visibility into that data or, worse, ceding ownership of it is a structural problem that gets expensive to fix once a study is running.

In pharmaceutical development, sponsors routinely delegate data management to CROs, and the regulatory framework was built around that model. Medical device studies under ISO 14155 maintain sponsor responsibility differently. For lean clinical teams running three-person study operations, real-time access to your own data isn't a nice-to-have. It's a requirement for meaningful oversight.

A purpose-built EDC for device investigations should support eCRF design that reflects how device trials are actually structured, including adverse events tied to device deficiencies, per-procedure observations, and device-specific safety endpoints. It should give the sponsor direct monitoring access without routing requests through a CRO report cycle. And it should handle the compliance overhead: 21 CFR Part 11-compliant electronic signatures, audit trails, and system validation documentation, without requiring the sponsor to build that infrastructure from scratch. GG Clinical is Greenlight Guru's EDC platform built specifically for medical device clinical trials, covering pre-market investigations, PMCF studies, and long-term follow-up from a single system.

Why device studies are structurally different

Medical device clinical investigations under ISO 14155 and pharmaceutical trials covered by International Council for Harmonisation (ICH) E6 share a regulatory commitment to data integrity and subject safety, but they're operationally different in ways that affect almost every EDC requirement.

Device variability is higher. A drug compound has defined pharmacological properties. A medical device interacts differently across patients depending on anatomy, implant size, surgeon technique, and procedural factors that are difficult to fully anticipate in protocol design. Your eCRFs need to capture that variability. They also need to flex when the protocol evolves mid-study, which it often does. Protocols change because the device behaves differently than anticipated, or because an early site experience reveals a better way to measure the primary endpoint.

Study designs are more heterogeneous. A device manufacturer might run a first-in-human feasibility study with 10 subjects, a multi-site pivotal trial with 200, and a PMCF registry simultaneously. A single pharmaceutical trial structure requires significant reconfiguration for each. That reconfigeration costs time, which is the one resource early-stage clinical teams consistently underestimate.

Site management in device studies typically involves a smaller number of sites than pharma trials, but those sites vary significantly in technical capability. Investigators at an academic medical center, a private surgical practice, and a hospital research department do not approach EDC training and adoption the same way. A platform that clinical sites find hard to use produces poor data quality regardless of how well the eCRF was designed.

PMCF adds a post-market data dimension that most EDC platforms weren't designed to handle. Under EU MDR, manufacturers have an ongoing obligation to collect post-market clinical data through surveys, registries, and long-term follow-up. That's a different data collection model than an interventional study, and it typically requires a different eCRF structure. An EDC that can't support both pre-market and post-market collection from a single platform creates fragmentation in the manufacturer's clinical data program. See our PMCF planning guide for more on how post-market collection requirements factor into study design.

Remote monitoring has also become standard practice for most device investigations. Source data verification happens remotely for efficiency. The EDC needs to support tiered verification and give monitors the real-time access they need to complete that work without depending on CRO report packages.

What the wrong system costs

The cost of choosing the wrong EDC system for clinical trials usually shows up after a study is already running. By then, the options are to absorb the cost or rebuild, and rebuilding mid-study is expensive in time, regulatory risk, and team bandwidth.

Spreadsheets are the path of least resistance for early-stage manufacturers. No procurement process, no training requirements, no upfront cost. The problems become visible as the study scales. Manual data entry creates transcription errors that accumulate across sites and time points. Spreadsheets have no audit trail. Version control becomes a full-time job. When a regulatory body asks for your dataset, you're reconstructing it from fragmented files. The cost difference between EDC and paper-based data collection becomes concrete when a study reaches regulatory review. One manufacturer running simple clinical studies in Excel reached the point of EU MDR compliance review and couldn't demonstrate data integrity to their notified body. They spent weeks rebuilding records before they could submit. The time cost alone exceeded what a purpose-built EDC would have cost to run the entire study.

CRO-bundled EDC is common for first-time manufacturers who don't fully understand what they're signing. The CRO provides the platform as part of the service contract. Setup is easy. The problems come when the study ends or the relationship changes. When your data lives on a CRO's infrastructure, your access is contingent on the service relationship. Export rights are sometimes buried in contract language that doesn't look like a problem until you need to reuse your dataset for a follow-on study, pivot to a different CRO, or run your own analysis ahead of a submission. See our guide on choosing a CRO for what data ownership terms to look for in a CRO contract.

Enterprise pharma EDC platforms have name recognition for a reason. They've run thousands of trials. But for a lean device team running a 30-site pivotal investigation, the implementation timeline, licensing model, and configuration overhead of an enterprise platform is rarely proportionate to the study requirements. You pay for capability you don't use and spend the first quarter of your study in implementation rather than enrollment.

What to look for in EDC software for medical devices

Evaluating EDC systems comes down to a handful of criteria that general EDC checklists miss. The most important is ISO 14155 alignment. It should be built into the platform, not added through configuration. Its requirements for protocol structure, safety reporting, and documentation differ from ICH E6. A platform built for pharmaceutical good clinical practice (GCP) and adapted for devices will show that mismatch during an audit. Ask vendors directly: which ISO 14155 requirements are handled natively, and which require custom setup? Our ISO 14155 guide covers the standard's key requirements in detail.

eCRF design flexibility should be accessible to your clinical team, not locked behind IT configuration. Device studies require forms that can be modified as the protocol evolves, that handle unscheduled events and adverse events without corrupting the core data model, and that can capture both structured endpoint data and free-text clinical observations. The way a form is structured affects data completeness throughout the study. See our eCRF completion guidelines for what good eCRF design looks like in practice.

Real-time monitoring access should not route through a CRO. You should be able to see query status, protocol deviations, site performance, and data completeness directly from your sponsor account, as the data is entered. ISO 14155 places sponsor oversight responsibility with the manufacturer. That responsibility is difficult to fulfill if your visibility into the study depends on reports that arrive days after the fact.

21 CFR Part 11 compliance and system validation documentation should be provided by the vendor. For a lean team, that validation burden is a significant overhead. A purpose-built EDC handles system validation and provides the documentation package your inspectors will ask for. For manufacturers operating under FDA jurisdiction, our guide to data management in FDA-regulated clinical trials covers the documentation requirements in detail. Our GCP compliance guide covers what Part 11 audit trail requirements look like in practice.

Data export should be unconditional. Ask every vendor the same question: what happens to my data if I end my contract, move to a different CRO, or switch platforms? If the answer involves additional fees, a waiting period, or a proprietary format, that's a lock-in risk worth quantifying before you sign.

PMCF support should be native, not an add-on. If you're operating under EU MDR or planning post-market clinical obligations, your EDC should support survey-based data collection, registry enrollment, and long-term follow-up in the same platform where you ran your pre-market investigation. Clinical evidence doesn't stop at market clearance.

When you are ready to move from understanding what to look for to running the actual vendor evaluation, our EDC selection guide for device investigations covers the question bank, pass/fail criteria, and internal case-building framework.

Study design principles that apply regardless of platform

No EDC compensates for a poorly designed study. These principles apply whether you're running your first EDC clinical trial on a purpose-built platform or migrating from spreadsheets mid-study.

Design your eCRFs from your statistical analysis plan, working backward. Every field that doesn't map to a defined endpoint is noise that will slow down database lock and create queries that consume team time.

Build and test in a staging environment before going live. Run realistic scenarios before the first subject is enrolled: unscheduled visits, protocol deviations, adverse events tied to device malfunction. Issues found in testing cost nothing. The same issues found mid-study cost significantly more.

Start building before regulatory approval. Ethics committee and competent authority review takes time. Use that window to finalize eCRF design, train investigation sites, and validate your monitoring workflows. When approval comes, you can begin enrollment without delay.

Stay close to your study even when using a CRO. Delegating study operations to a CRO doesn't transfer the sponsor's oversight responsibility under ISO 14155. Real-time access to your data means flagging issues as they emerge rather than discovering them in a CRO data package that arrives after the monitoring visit.

Simpler eCRFs produce better data. Remove any field that doesn't answer a specific question the study is designed to address. The most common data quality problems in device studies trace back to forms that tried to capture everything rather than the things that matter.

What manufacturers say after making the switch

Bernafon, a hearing aids manufacturer, transitioned from a free EDC platform that was increasing data management time and making eCRF creation cumbersome. The move to a purpose-built system made each eCRF page straightforward to build and reduced data export time to near zero.

Loop Medical, a Class II device company, was managing international studies on paper. The lack of real-time visibility across sites created delays and data gaps. After switching, they set up a new study in a couple of weeks without working on it full time. In their words, it removed headaches from data collection and real-time access saved both time and money.

InnoCon Medical needed real-time data for feasibility studies and wanted a system that investigation sites would actually find easy to use. Their clinical project manager described it as simple for sites to use, a detail that matters significantly when site adoption determines data completeness.

Kerecis was running clinical studies in Excel, which was not EU MDR compliant and created time-consuming manual data entry. After switching, they eliminated manual input entirely and achieved compliance in both the US and EU.

The consistent pattern across these manufacturers is not that the EDC solved all their clinical problems. It's that removing the data collection friction freed team capacity to focus on the actual study.

GG Clinical

GG Clinical is Greenlight Guru's purpose-built EDC for medical devices. It manages the full investigation lifecycle: eCRF design and modification, site and subject management, query handling, real-time sponsor monitoring, and regulatory reporting. ISO 14155 and 21 CFR Part 11 compliance are native to the platform. Greenlight Guru provides the system validation documentation, so sponsors don't build it themselves.

The platform covers pre-market investigations, PMCF surveys and registries, and long-term follow-up from the same interface. Manufacturers export their complete dataset in any standard format at any point in the study, without conditions or additional fees. CRO collaborators get site-level access without reaching sponsor-level monitoring views. Onboarding is handled by clinical operations specialists, not software engineers.

GG Clinical has supported more than 500 studies across multiple regulatory jurisdictions. Most teams go from study initiation to first subject enrolled in days.

Get a demo of GG Clinical

Pall Johannesson is a clinical specialist at Greenlight Guru with experience supporting medical device manufacturers through study design, EDC implementation, and regulatory submissions in the EU and US.